Article
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.
Nature medicine - 1 Jan 2024
Desai Jayesh, Alonso Guzman, Kim Se Hyun, Cervantes Andres, Karasic Thomas, Medina Laura, Shacham-Shmueli Einat, Cosman Rasha, Falcon Alejandro, Gort Eelke, Guren Tormod, Massarelli Erminia, Miller Wilson H, Paz-Ares Luis, Prenen Hans, Amatu Alessio, Cremolini Chiara, Kim Tae Won, Moreno Victor, Ou Sai-Hong I, Passardi Alessandro, Sacher Adrian, Santoro Armando, Stec Rafal, Ulahannan Susanna, Arbour Kathryn, Lorusso Patricia, Luo Jia, Patel Manish R, Choi Yoonha, Shi Zhen, Mandlekar Sandhya, Lin Mark T, Royer-Joo Stephanie, Chang Julie, Jun Tomi, Dharia Neekesh V, Schutzman Jennifer L, Han Sae-Won
Abstract excerpt
KRAS G12C mutation is prevalent in ~4% of colorectal cancer (CRC) and is associated with poor prognosis. Divarasib, a KRAS G12C inhibitor, has shown modest activity as a single agent in KRAS G12C-positive CRC at 400 mg. Epidermal growth factor receptor has been recognized as a major upstream activator of RAS-MAPK signaling, a proposed key mechanism of resistance to KRAS G12C inhibition in CRC. Here, we report on...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.